NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2024-04-04 pm EDT			5-day change	1st Jan Change
1.54 ^USD	-1.28%		0.00%	+79.28%

Apr. 05	NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index	CI
Apr. 05	The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.	CI

Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 06, 2021 at 02:27 pm EDT

NGM Biopharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was USD 21.575 million compared to USD 24.364 million a year ago. Operating loss was USD 27.845 million compared to USD 20.670 million a year ago. Net loss was USD 27.544 million compared to USD 19.115 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.28 a year ago.

Latest news about NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index	Apr. 04	CI
The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.	Apr. 04	CI
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P Global BMI Index	Apr. 04	CI
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P TMI Index	Apr. 04	CI
North American Morning Briefing : Investors -2-	Mar. 18	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Raymond James Downgrades NGM Biopharmaceuticals to Market Perform From Outperform	Mar. 12	MT
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
B. Riley Lowers NGM Biopharmaceuticals' PT to $1.55 From $3.50 on Heels of Announced Sale Agreement With Affiliates of The Column Group, Keeps Buy Rating	Feb. 28	MT
TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $1.55 From $4	Feb. 28	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Sector Update: Health Care Stocks Weaker Monday Afternoon	Feb. 26	MT
Sector Update: Health Care	Feb. 26	MT
NGM Biopharmaceuticals Enters Merger Deal With Affiliates of The Column Group	Feb. 26	MT
Atlas Neon Parent, Inc. entered into a definitive Agreement to acquire an unknown majority stake in NGM Biopharmaceuticals, Inc. for approximately $140 million.	Feb. 25	CI
NGM Biopharmaceuticals Provides Update on Cancer Treatment Trial -- Shares Rise	Jan. 09	MT
NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need	Jan. 09	CI
NGM Biopharmaceuticals Stock Soars as Shareholder Group Expresses Takeover Interest	Jan. 02	MT
NGM Biopharmaceuticals Receives Non-Binding Expression of Interest from Column Group	Jan. 01	CI
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
B. Riley Lowers NGM Biopharmaceuticals' Price Target to $3.50 From $7, Maintains Buy Rating	Nov. 22	MT
NGM Biopharmaceuticals Says Phase 2b Trial of Potential Cirrhosis Treatment Meets Primary Endpoint	Nov. 13	MT

Chart NGM Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NGM BIOPHARMACEUTICALS, INC.	+79.28%	129M
VERTEX PHARMACEUTICALS INCORPORATED	-1.27%	105B
REGENERON PHARMACEUTICALS, INC.	+3.41%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.46%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.53%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.20%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.61%	10.99B

Bio Therapeutic Drugs